TAGline Spring 2018
Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.
In a State of Disunion: HIV, TB, and HCV Elimination Policies and Priorities Under the Trump Administration
By Suraj Madoori During Trump’s first-ever State of the Union address on January 30, activists observed a dearth of clear priorities to eliminate HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the U.S. Science and longstanding bipartisan interest in…
It’s up to You, New York: Moving towards HCV Elimination in the Empire State
By Annette Gaudino Governor Andrew Cuomo’s March 16 announcement committing New York State (NYS) to ending the hepatitis C virus (HCV) epidemic was the culmination of years of advocacy on a path that paralleled—and is built upon—the state’s nation leading…
World Health Organization Guidelines for the Treatment of Multidrug-Resistant Tuberculosis
Letter to Dr. Tedros Adhanom Ghebreyesus, Director-General, WHO, and Dr. Tereza Kasaeva, Global TB Program Director.
Suboptimal Immune Recovery on Antiretroviral Therapy: Causes, Consequences, and the Search for Solutions
On November 29, 2017, Treatment Action Group (TAG) hosted a webinar on suboptimal immune recovery despite HIV suppression by antiretroviral therapy. Presented by Richard Jefferys, TAG’s Basic Science, Vaccines and Cure Project Director, the webinar reviewed the possible causes and…
Viekira XR and Technivie Fact Sheet
Updated February 2017 The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream at least 12 weeks after treatment is finished). What is Viekira XR? Viekira XR is a combination…
Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug
Public health groups welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development of a promising tuberculosis drug and lead to improved treatment options for people living with TB.
TAG Responds to the Release of the World Health Organization’s 2016 Global Tuberculosis Report
TB is a preventable, curable disease, and the dismal lack of progress against reversing the TB epidemic is unacceptable. Last year, the World Health Organization (WHO) reported that TB had overtaken HIV as the world's leading cause of death from an infectious disease, and this year the WHO numbers show that the TB epidemic is larger than previously estimated
Epclusa Fact Sheet
Epclusa is a fixed-dose combination of two HCV-fighting drugs (sofosbuvir and velpatasvir) in one pill. In the United States, Epclusa is approved for people with all hepatitis C genotypes (1–6) who are 18 years of age and older.
Zepatier Fact Sheet
Zepatier is two hepatitis C virus-fighting drugs in one tablet. These drugs block different steps of the virus lifecycle. In the United States, Zepatier is approved for people who are over 18 years old with hepatitis C genotype 1 or genotype 4.